Hansa Biopharma announces increase in number of shares and votes

Lund, Sweden July 31, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces that the Company’ s registered share capital and number of outstanding shares and votes have increased during the month of July. 

As previously communicated, the board of directors of Hansa Biopharma resolved on a share issue of 4,447,345 ordinary shares, on July 8, 2020, by virtue of authorization by the Annual General Meeting held on June 23, 2020. 

As of July 31, 2020, the total number of registered and outstanding shares of Hansa Biopharma amounts to 45,894,909, of which 44,473,452 are ordinary shares and 1,421,457 are class C shares. As of today, the number of votes in Hansa Biopharma amounts to 44,615,597.7 and the registered share capital amounts to SEK 45,894,909.

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.

Subscribe

Documents & Links